KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Non-Current Liabilities (2018 - 2025)

TherapeuticsMD's Total Non-Current Liabilities history spans 10 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 7.48% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, down 7.48%, while the annual FY2025 figure was $9.9 million, 7.48% down from the prior year.
  • Total Non-Current Liabilities reached $9.9 million in Q4 2025 per TXMD's latest filing, down from $10.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $272.7 million in Q1 2022 to a low of $9.9 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $86.2 million, with a median of $21.3 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: grew 8.23% in 2021, then plummeted 90.29% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $261.0 million in 2021, then tumbled by 79.23% to $54.2 million in 2022, then plummeted by 75.31% to $13.4 million in 2023, then dropped by 20.01% to $10.7 million in 2024, then decreased by 7.48% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Total Non-Current Liabilities are $9.9 million (Q4 2025), $10.4 million (Q3 2025), and $10.4 million (Q2 2025).